[63]
In Novopharm's submission, rather than being "of little assistance," the reasoning in
Merck Frosst
is both helpful and applicable to the case at bar. Abbott already knows everything that is public about PREVACID; it is Abbott's product. What Abbott wants disclosed are the specific documents submitted by Novopharm to Health Canada and the context in which the information within those documents was provided. That is the very information that is relevant to this case, is most confidential and would cause the most damage to Novopharm if it were made public.